Strategic Investment Advisors MI Grows Position in United Therapeutics Co. (NASDAQ:UTHR)

Strategic Investment Advisors MI raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,983 shares of the biotechnology company’s stock after buying an additional 95 shares during the quarter. Strategic Investment Advisors MI’s holdings in United Therapeutics were worth $2,111,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in UTHR. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in United Therapeutics by 52.7% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 8,565 shares of the biotechnology company’s stock valued at $2,728,000 after buying an additional 2,955 shares in the last quarter. Toronto Dominion Bank boosted its holdings in shares of United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares during the period. Dark Forest Capital Management LP purchased a new position in shares of United Therapeutics in the 2nd quarter worth approximately $400,000. MBB Public Markets I LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth approximately $1,079,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of United Therapeutics by 37.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 98,783 shares of the biotechnology company’s stock worth $31,467,000 after purchasing an additional 26,840 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.3 %

UTHR opened at $370.83 on Monday. The firm has a market cap of $16.56 billion, a price-to-earnings ratio of 16.29, a PEG ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a fifty day moving average price of $365.19 and a 200-day moving average price of $356.03.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.38 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Argus boosted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $378.36.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This represents a 12.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $940,373.07. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 139,048 shares of company stock valued at $52,435,099. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.